metronivet 1000 mg tabletter
cp-pharma handelsgesellschaft mbh - metronidazol - tabletter - 1000 mg
metronivet 500 mg tabletter
cp-pharma handelsgesellschaft mbh - metronidazol - tabletter - 500 mg
rozex 7,5 mg/g creme
medartuum ab - metronidazol - creme - 7,5 mg/g
precosa 250 mg kapsler, hårde
biocodex - saccharomyces boulardii cncm i-745, frysetørret - kapsler, hårde - 250 mg
precosa 250 mg pulver til oral suspension, enkeltdosisbeholder
biocodex - saccharomyces boulardii cncm i-745, frysetørret - pulver til oral suspension, enkeltdosisbeholder - 250 mg
cefotaxim "sandoz" 1 g pulver til injektions-/infusionsvæske, opløsning
sandoz gmbh - cefotaximnatrium - pulver til injektions-/infusionsvæske, opløsning - 1 g
cefotaxim "sandoz" 2 g pulver til injektions-/infusionsvæske, opløsning
sandoz gmbh - cefotaximnatrium - pulver til injektions-/infusionsvæske, opløsning - 2 g
cefotaxim "sandoz" 0,5 g pulver til injektionsvæske, opløsning
sandoz gmbh - cefotaximnatrium - pulver til injektionsvæske, opløsning - 0,5 g
zinplava
merck sharp & dohme b.v. - bezlotoxumab - enterocolitis, pseudomembranøs - immune sera og immunoglobuliner, - zinplava er indiceret til forebyggelse af tilbagefald af clostridium difficile infektion (cdi) hos voksne med høj risiko for gentagelse af cdi.
zavicefta
pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibakterielle midler til systemisk brug, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..